Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06921928 · ClinicalTrials.gov registry record · Phase 1
Study for AZD4360 in Participants With Advanced Solid Tumours
A Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 17
- Study locations
NCT06921928: Recruiting Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.
NCT06921928 is a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 117 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (63% lower). The trial reports 17 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06921928, a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Primary Outcome
To investigate the safety and tolerability, and to determine the Maximum Tolerated Dose (MTD) and/or a Recommended Phase II Dose (R2PD) of AZD4360 in previously treated participants with advanced solid tumours, through the assessment of Dose Limiting Toxicities, Adverse Events and Severe Adverse Events.
Conditions Studied
Interventions
- DRUG AZD4360
Study Locations (17)
Other
- Research Site - Beijing
- Research Site - Chengdu
- Research Site - Shanghai
- Research Site - Wuhan
- Research Site - Berlin
- Research Site - Dresden
- Research Site - Frankfurt
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Kōtoku
- Research Site - Glasgow
- Research Site - Leeds
- Research Site - London
- Research Site - Oxford
California
- Research Site - Santa Monica
Rhode Island
- Research Site - Providence
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-12-16 |
| Phase | Phase 1 |
What NCT06921928 shows while recruiting
NCT06921928 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (63% lower).
The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD4360 is the first listed.
NCT06921928 lists 17 locations in 4 states (Other, California, Rhode Island).
Frequently Asked Questions
What is clinical trial NCT06921928 about?
NCT06921928 is a clinical study titled "Study for AZD4360 in Participants With Advanced Solid Tumours". The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
What is the current status of trial NCT06921928?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2025-04-29. Estimated completion is 2027-12-16.
What conditions does trial NCT06921928 study?
This clinical trial studies the following conditions: Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06921928?
The interventions under investigation include: AZD4360 (DRUG).
Who is sponsoring clinical trial NCT06921928?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06921928 being conducted?
This trial has 17 study locations across California, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06921928's enrollment target sits among peer trials
117 76th of 153 higher than 77 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
- NCT05277558 · 117 participants
Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI